Dr. Valsamo (. Anagnostou

Dr. Anagnostou is an Associate Professor of Oncology, co-director of the Upper Aerodigestive Malignancies Program, director of the Thoracic Oncology Biorepository, leader of Precision Oncology Analytics and co-leader of the Molecular Tumor Board and the Thoracic Oncology Precision Medicine Center of Excellence in the Sidney Kimmel Cancer Center at Johns Hopkins. She has established the Molecular Oncology laboratory that seeks to understand the genomic wiring of response and resistance to immunotherapy through integrative genomic, transcriptomic, single-cell and liquid biopsy analyses of tumor and immune evolution. Dr. Anagnostou graduated from Medical School of the National and Kapodistrian University of Athens, Greece and received a PhD from the same institution. After completing her internal medicine residency at Yale-New Haven Hospital, she subsequently trained in Medical Oncology at Johns Hopkins. Dr. Anagnostou is a translational cancer investigator, focusing on large-scale genomic and liquid biopsy analyses in human cancers. Her group has discovered novel genomic mechanisms of response and resistance to immunotherapy and her research is particularly focused on understanding the molecular mechanisms of response and resistance to these therapies, capturing these by minimally invasive methods and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients. She is the international study chair of the first ctDNA-based molecular response adaptive immuno-chemotherapy clinical trial for metastatic non-small cell lung cancer (NCT04093167). Dr. Anagnostou's long term goal is to transform medical oncology to personalized molecular oncology, where treatment decisions are tailored to cancer genomics and molecular real-time response assessments informed by liquid biopsies.

Dr. Anagnostou is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, and Esophageal Cancer.

She is actively involved in clinical research, co-authoring 112 peer reviewed articles and participating in 1 clinical trial.